Peptides for Strength vs Mass: Which Goal Wins (2026)

Peptides for Strength vs Mass: Which Goal Wins (2026) IGF-1 for site-specific strength. GHRH+GHRP for systemic mass. Picking the right compound for powerlifting vs bodybuilding. IGF-1 LR3, 4-6 weeks, post-workout, injected near target muscle. IGF-1 LR3 is the strongest direct anabolic tool in the peptide world. It binds IGF-1 receptors with extended half-life compared to native IGF-1 and concentrates locally when injected near target tissue. Advanced strength users run short cycles (4-6 weeks maximum) focused on bringing up weak points. Why it's in the strength tier: site-specific fiber hypertrophy supports force output in lagging muscles more precisely than systemic GH elevation. The lifter who can't lock out a deadlift doesn't need more fat loss — they need thicker spinal erectors, and IGF-1 LR3 injected intramuscularly in that area is one way to get there. Trade-offs: hypoglycemia risk (cross-reactivity with insulin receptor at high doses), short cycle length required (receptor desensitization), mandatory bloodwork. Protocol: 20-50 mcg post-workout, intramuscular near target muscle, 4-6 days per week. Fast-acting carbs on hand. Deep dive: Best IGF-1 LR3 Vendors | IGF-1 LR3 Dosing Guide Ranked by price, COA availability, and reputation Follistatin-344, 4 weeks, adjunct on top of a GHRH+GHRP base. Follistatin binds and neutralizes myostatin — the protein that actively limits muscle growth. The Kota 2009 nonhuman primate study showed follistatin gene delivery produced durable muscle size and strength increases. Human data for peptide injection is limited. Why it's in the strength tier: myostatin inhibition tends to produce disproportionate strength gains relative to mass gains in animal models. Double-muscled cattle (Belgian Blue) have the same pattern — much more muscle + more force, less fat. Protocol: 100 mcg follistatin-344 daily for 4 weeks, subcutaneous, stacked on top of CJC+ipa or tesa+ipa. Experimental. Deep dive: Follistatin-344 Dosing Guide BPC-157, 4-8 weeks, subcutaneous or localized near injury. BPC-157's strength angle isn't direct hypertrophy — it's connective tissue integrity. For powerlifters accumulating tendon/ligament wear from repeated heavy lifting, BPC-157 accelerates repair and supports higher training volumes before breakdown. A strength lifter who can train 4x/week instead of 3x/week because their elbows don't hurt will produce more strength gains over time than any direct anabolic peptide at the same dose. Protocol: 250-500 mcg subcutaneous, twice daily, localized near any problem joint or tendon. Deep dive: Best BPC-157 Vendors | BPC-157 Dosing Guide TB-500, 4-6 weeks, subcutaneous. Pairs with BPC-157 for a broader repair stack. Good for powerlifters dealing with accumulated multi-site wear (shoulders, lower back, knees all cranky at once). Deep dive: Best TB-500 Vendors | TB-500 Dosing Guide Base: CJC-1295 + ipamorelin, 100 mcg + 100 mcg pre-bed, 12-16 weeks Add weeks 8-12: IGF-1 LR3 30 mcg post-workout, 4 days/week Add as needed: BPC-157 for sore joints Expected outcome: 3-5 lb lean mass, modest strength gains, better training frequency. Base: Tesamorelin + ipamorelin, 2 mg + 100-200 mcg pre-bed, 12-16 weeks Add weeks 4-8: Follistatin-344 100 mcg daily for 4 weeks Continuous: BPC-157 250 mcg twice daily for training volume support Expected outcome: 4-5 lb lean mass, visible physique transformation, meaningful strength signal on major lifts. For mass (bodybuilding-leaning): 4-6 sessions per week 10-20 working sets per muscle group per week Rep ranges of 6-15 Moderate intensity (65-85% 1RM) Short-to-medium rest intervals (60-120 sec) For strength (powerlifting-leaning): 3-5 sessions per week Fewer total sets, higher intensity Rep ranges of 1-5 High intensity (85-95% 1RM) Long rest intervals (3-5 min) Running a mass-focused peptide stack with strength-focused training still works, but you'll leave gains on the table. Match the stack to the training. Both tiers: baseline IGF-1, fasting glucose, HbA1c, CMP, lipid panel. Mass stacks: standard 4-week IGF-1 check, 12-week full panel. Strength stacks with IGF-1 LR3: more frequent glucose monitoring (weekly fasting glucose during active IGF-1 LR3 use). Fast-acting carbs on hand every training session. Best Peptides for Muscle Growth — anchor ranking Best Peptides for Bulking — mass-focused protocols Best Peptides for Post-Workout Recovery — training volume support Peptides vs SARMs vs Steroids — cross-category comparison Peptide Muscle Timeline — expectations by stack IGF-1 LR3 Dosing Guide — protocol detail Follistatin-344 Dosing Guide — protocol detail 1 Bowers CY, et al. GH-releasing peptide acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. 2108187 2 Falutz J, et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Clin Endocrinol Metab. 2010;95(9):4291-4304. 20101189 3 Adrian S, et al. Tesamorelin decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging. 2019;8(3):154-159. 31237318 4 Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. 16352683 5 Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. 9849822 6 Nass R, et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;149(9):601-611. 18981485 7 Kota J, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15. 20368179 8 Pandya N, et al. GHRP-6 requires endogenous hypothalamic GHRH for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189. 9543138